The five most commonly used intact parathyroid hormone assays are useful for screening but not for diagnosing bone turnover abnormalities in CKD-5 patients
- PMID: 19640382
- PMCID: PMC4501021
- DOI: 10.5414/cnp72005
The five most commonly used intact parathyroid hormone assays are useful for screening but not for diagnosing bone turnover abnormalities in CKD-5 patients
Abstract
Background/aims: Assessment of bone turnover for management of renal osteodystrophy is part of routine care in chronic kidney disease Stage 5 (CKD-5) patients. Measurement of intact parathyroid hormone (iPTH) is the most commonly used surrogate marker for bone turnover in these patients. The current study was conducted to evaluate the predictive value of the five most commonly used iPTH assays for bone turnover.
Methods: In a cross-sectional study, 84 CKD-5 patients underwent bone biopsy and blood drawings for determination of iPTH and total serum alkaline phosphatase (AP).
Results: Histologically, patients presented with a broad range of bone turnover abnormalities as determined by activation frequency and bone formation rate/bone surface. Results of the five iPTH assays in each patient correlated but were significantly different. There were also significant differences between iPTH measurements at the same bone turnover level. Using Kidney Disease Outcome Quality Initiative recommended iPTH ranges, all assays showed comparably poor diagnostic performance. At 80% specificity, cut-off values of the 5 iPTH assays for low bone turnover varied from 165 to 550 pg/ml and for high bone turnover from 404 to 1,003 pg/ml. Sensitivities at these cutoffs remained below acceptable standards. Addition of AP measurements to iPTH did not improve diagnostic accuracy.
Conclusions: Precise assessment of bone turnover will require utilization of established and novel bone markers reflecting effects of bone turnover rather than measuring only iPTH or other effectors.
Conflict of interest statement
All other authors have no competing financial interest.
Figures



Similar articles
-
Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy.J Am Soc Nephrol. 2018 May;29(5):1557-1565. doi: 10.1681/ASN.2017050584. Epub 2018 Mar 19. J Am Soc Nephrol. 2018. PMID: 29555831 Free PMC article.
-
[Diagnostic accuracy study comparing total alkaline phosphatase with intact parathyroid hormone 1-84 for the diagnosis of high turnover renal osteodystrophy in chronic renal failure on hemodialysis].Medwave. 2014 Sep 3;14(8):e6014. doi: 10.5867/medwave.2014.08.6014. Medwave. 2014. PMID: 25340338 Spanish.
-
Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients.J Am Soc Nephrol. 1996 Mar;7(3):506-12. doi: 10.1681/ASN.V73506. J Am Soc Nephrol. 1996. PMID: 8704118
-
[Biochemical and histological spectrum of renal osteodystrophy in Argentina].Nefrologia. 2003;23 Suppl 2:47-51. Nefrologia. 2003. PMID: 12778854 Review. Spanish.
-
Parathyroid hormone assays--evolution and revolutions in the care of dialysis patients.Clin Nephrol. 2003 May;59(5):313-8. doi: 10.5414/cnp59313. Clin Nephrol. 2003. PMID: 12779091 Review.
Cited by
-
Comparison of Second- and Third-Generation Parathyroid Hormone Test Results in Patients with Chronic Kidney Disease.Med Sci Monit. 2020 Dec 24;26:e928301. doi: 10.12659/MSM.928301. Med Sci Monit. 2020. PMID: 33361742 Free PMC article.
-
Advanced glycosylation end products promote the progression of CKD-MBD in rats, and its natural inhibitor, quercetin, mitigates disease progression.Naunyn Schmiedebergs Arch Pharmacol. 2024 Dec;397(12):9675-9688. doi: 10.1007/s00210-024-03217-1. Epub 2024 Jun 22. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38907848
-
Intact PTH combined with the PTH ratio for diagnosis of bone turnover in dialysis patients: a diagnostic test study.Am J Kidney Dis. 2010 May;55(5):897-906. doi: 10.1053/j.ajkd.2009.12.041. Epub 2010 Mar 27. Am J Kidney Dis. 2010. PMID: 20347512 Free PMC article.
-
Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy.J Am Soc Nephrol. 2018 May;29(5):1557-1565. doi: 10.1681/ASN.2017050584. Epub 2018 Mar 19. J Am Soc Nephrol. 2018. PMID: 29555831 Free PMC article.
-
The case for routine parathyroid hormone monitoring.Clin J Am Soc Nephrol. 2013 Feb;8(2):313-8. doi: 10.2215/CJN.04650512. Epub 2012 Oct 4. Clin J Am Soc Nephrol. 2013. PMID: 23037984 Free PMC article.
References
-
- Barreto FC, Barreto DV, Moyses RM, Neves KR, Canziani ME, Draibe SA, Jorgetti V, Carvalho AB. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int. 2008;73:771–777. - PubMed
-
- Berson SA, Yalow RS. Immunochemical heterogeneity of parathyroid hormone in plasma. J Clin Endocrinol Metab. 1968;28:1037–1047. - PubMed
-
- Bervoets AR, Spasovski GB, Behets GJ, Dams G, Polenakovic MH, Zafirovska K, Van Hoof VO, De Broe ME, D’Haese PC. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis. 2003;41:997–1007. - PubMed
-
- Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barre M, D’Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab. 1996;81:3923–3929. - PubMed
-
- Brossard JH, Yamamoto LN, D’Amour P. Parathyroid hormone metabolites in renal failure: bioactivity and clinical implications. Semin Dial. 2002;15:196–201. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical